An Unusual Case of Sustained Ventricular Tachycardia From Acute Pulmonary Embolism

Birchak, John; Khan, Arfaat; Singh, Gurjit; Schuger, Claudio; Maskoun, Waddah

doi:10.1016/s0735-1097(20)33447-1

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case of multifocal ventricular tachycardia was preceded by electrocardiography (ECG) findings of ST-segment elevation in a patient with COVID-19 ( 20 ). A case of acute bilateral pulmonary embolism in a COVID-19 patient later developed sustained monomorphic ventricular tachycardia with syncope requiring cardioversion ( 21 ). Also, some of the “repurposed drugs'' used for the management of COVID-19 have known risk of QTc prolongation, which could lead to torsades de pointes (TdP) ( 22 ).…”

Section: Data On Arrhythmia From Previous Epidemics and The Current Cmentioning

confidence: 99%

Arrhythmias and COVID-19

Dherange

Lang

Qian

et al. 2020

JACC: Clinical Electrophysiology

152

156

View full text Add to dashboard Cite

Current understanding of the impact of coronavirus disease-2019 (COVID-19) on arrhythmias continues to evolve as new data emerge. Cardiac arrhythmias are more common in critically ill COVID-19 patients. The potential mechanisms that could result in arrhythmogenesis among COVID-19 patients include hypoxia caused by direct viral tissue involvement of lungs, myocarditis, abnormal host immune response, myocardial ischemia, myocardial strain, electrolyte derangements, intravascular volume imbalances, and drug sides effects. To manage these arrhythmias, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine. As COVID-19 infection continues to prevail with a potential for future surges, more data are required to better understand pathophysiology and to validate management strategies.

show abstract

Section: Data On Arrhythmia From Previous Epidemics and The Current Cmentioning

confidence: 99%

Arrhythmias and COVID-19

Dherange

Lang

Qian

et al. 2020

JACC: Clinical Electrophysiology

152

156

View full text Add to dashboard Cite

show abstract

“…Although rare, serious systemic infections such as myocarditis have been reported in connection with COVID-19, myocarditis, an inflammatory condition affecting the myocardium, arises from a broad spectrum of both infectious and non-infectious causes. Many different viruses have been implicated, including the Middle East Respiratory Syndrome (MERS) coronavirus, which closely resembles SARS-CoV-2 [ 84 , 85 , 86 , 87 ]. Myocarditis is suspected based on elevated troponins in the patient’s blood, cardiac arrhythmias or diffuse ST-segment elevation on electrocardiogram (ECG), and impaired contractility of the left ventricular wall (regional or global hypokinesia) on echocardiography.…”

Section: Discussionmentioning

confidence: 99%

Cardiac Involvement in COVID-19 Patients: A Contemporary Review

Carretta

Silva

D’Agostino

et al. 2021

Infectious Disease Reports

View full text Add to dashboard Cite

Background: The widely variable clinical manifestations of SARS-CoV2 disease (COVID-19) range from asymptomatic infections to multiple organ failure and death. Among the organs affected is the heart. This does not only affect people who already have previous cardiovascular problems, but also healthy people. This is a reason not to overlook any symptoms or to perform targeted examinations, even if apparently unrelated to the heart, for quick recognition and timely therapy. Aim of the study: This review recapitulates the current state of knowledge on the potential mechanisms and manifestation of myocarditis in patients with COVID-19 infection. Methods: A web-based search of published data was performed for all relevant studies on patients diagnosed with a COVID-19-induced acute myocarditis, and a total of 50 reports were included. The analysis of the studies evaluated highlights a male predominance, with the average age of patients being 55 years. The most common presenting symptoms included fever, shortness of breath, cough, and chest pain. Among ECG changes, non-specific ST-segment and T-wave amplitude alterations and ventricular tachycardia episodes were reported. Finally, we wanted to use a general evaluation without distinguishing between various countries, taking into consideration only the peer or reviewer, regardless of the declared value of the journals that have been published. Results and critical findings: The most common presenting symptoms included fever, shortness of breath, cough, and chest pain. Among ECG changes, non-specific ST-segment and T-wave amplitude alterations and ventricular tachycardia episodes were reported. In most patients, elevated levels of cardiac and inflammatory biomarkers were measured. Left ventricular dysfunction and hypokinesis were commonly exhibited symptoms. Cardiac Magnetic Resonance Imaging (CMRI) confirmed the diagnosis of myocarditis with features of cardiac edema and cardiac injury. Nine patients underwent histopathological examination. Treatment with corticosteroids and immunoglobulins was the most applied strategy following the administration of antivirals. Discussion: Despite the exponentially growing knowledge on the management of COVID-19 infection, current available data on SARS-CoV2-correlated myocarditis are still limited, and several difficulties may be encountered in the differential diagnosis of acute myocarditis in the context of COVID-19 disease. Conclusions: While diagnostic criteria and evaluation strategies for myocarditis are well described, no guidelines for the diagnosis and treatment of myocarditis in COVID-19 patients have yet been established. Therefore, further research is needed to advance the understanding of this disease process and define the most appropriate strategic approach in these patients.

show abstract

“…Furthermore, pulmonary hypertension which induces myocardial strain imbalance and myocardial ischemia also plays a significant role in the development of arrhythmia. [ 31 ]…”

Section: Pathophysiology Of Cardiac Arrhythmia In Coronavirus Disease-2019mentioning

confidence: 99%

Clinical Evidences and Pathophysiology of Cardiac Arrhythmia in the Era of Coronavirus Disease-2019

Hamad

2021

Heart Views

View full text Add to dashboard Cite

The coronavirus disease-2019 (COVID-19) is primarily caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a challenge to the clinician. Epidemiological studies unveiled the involvement of the cardiovascular system during the course of SARS-CoV-2 infection. The cardiac complications in patients with COVID-19 include myocarditis, heart failure, acute coronary syndrome, and cardiac arrhythmia. The pathophysiological states of the disease and multiple concurrent medications (unfamiliar to the clinicians) lead to a significant threat to arrhythmia. This review article hopes to elucidate the mechanisms of arrhythmias in COVID-19.

show abstract

An Unusual Case of Sustained Ventricular Tachycardia From Acute Pulmonary Embolism

Cited by 3 publications

References 0 publications

Arrhythmias and COVID-19

Arrhythmias and COVID-19

Cardiac Involvement in COVID-19 Patients: A Contemporary Review

Clinical Evidences and Pathophysiology of Cardiac Arrhythmia in the Era of Coronavirus Disease-2019

Contact Info

Product

Resources

About